1. Home
  2. AUPH vs VBTX Comparison

AUPH vs VBTX Comparison

Compare AUPH & VBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AUPH
  • VBTX
  • Stock Information
  • Founded
  • AUPH 1993
  • VBTX 2009
  • Country
  • AUPH Canada
  • VBTX United States
  • Employees
  • AUPH N/A
  • VBTX N/A
  • Industry
  • AUPH Biotechnology: Pharmaceutical Preparations
  • VBTX Major Banks
  • Sector
  • AUPH Health Care
  • VBTX Finance
  • Exchange
  • AUPH Nasdaq
  • VBTX Nasdaq
  • Market Cap
  • AUPH 999.8M
  • VBTX 1.2B
  • IPO Year
  • AUPH 1999
  • VBTX 2014
  • Fundamental
  • Price
  • AUPH $8.09
  • VBTX $23.25
  • Analyst Decision
  • AUPH Strong Buy
  • VBTX Strong Buy
  • Analyst Count
  • AUPH 2
  • VBTX 5
  • Target Price
  • AUPH $11.50
  • VBTX $30.40
  • AVG Volume (30 Days)
  • AUPH 1.3M
  • VBTX 461.9K
  • Earning Date
  • AUPH 05-05-2025
  • VBTX 04-22-2025
  • Dividend Yield
  • AUPH N/A
  • VBTX 3.44%
  • EPS Growth
  • AUPH N/A
  • VBTX 18.60
  • EPS
  • AUPH 0.04
  • VBTX 2.04
  • Revenue
  • AUPH $235,133,000.00
  • VBTX $416,460,000.00
  • Revenue This Year
  • AUPH $11.86
  • VBTX $14.51
  • Revenue Next Year
  • AUPH $24.96
  • VBTX $6.33
  • P/E Ratio
  • AUPH $197.25
  • VBTX $11.41
  • Revenue Growth
  • AUPH 33.97
  • VBTX 14.03
  • 52 Week Low
  • AUPH $4.77
  • VBTX $18.74
  • 52 Week High
  • AUPH $10.67
  • VBTX $31.62
  • Technical
  • Relative Strength Index (RSI)
  • AUPH 54.42
  • VBTX 52.51
  • Support Level
  • AUPH $7.59
  • VBTX $21.09
  • Resistance Level
  • AUPH $7.83
  • VBTX $22.66
  • Average True Range (ATR)
  • AUPH 0.34
  • VBTX 1.30
  • MACD
  • AUPH 0.04
  • VBTX 0.17
  • Stochastic Oscillator
  • AUPH 84.90
  • VBTX 78.69

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

About VBTX Veritex Holdings Inc.

Veritex Holdings Inc is engaged in the provision of commercial banking products and services to small to medium-sized businesses and professionals. The bank provides a range of banking services to individual and corporate customers, which include commercial and retail lending, and the acceptance of checking and savings deposits. It offers a suite of online banking solutions, including access to account balances, online transfers, online bill payment and electronic delivery of customer statements, as well as automated teller machines, and banking by telephone, mail and personal appointment. The company's primary sources of revenue are derived from interest and dividends earned on loans, debt and equity securities and other financial instruments.

Share on Social Networks: